Drug Profile
Somatropin - BresaGen
Alternative Names: Human growth hormone - BresaGenLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator BresaGen
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 03 Feb 2004 The directors of BresaGen have resigned and administrators have been appointed
- 03 Dec 2003 BresaGen plans to commercialise somatropin in collaboration with pharmaceutical partners
- 11 Jul 2001 Preclinical development for Somatotropin deficiency in Australia (Unknown route)